Retrospective observational study of the effectiveness of risankizumab and ixekizumab in patients with plaque psoriasis in real-world clinical practice
Risankizumab (anti-IL-23) and ixekizumab (anti-IL-17A) are biologic therapies for plaque psoriasis of proven efficacy in randomized clinical trials, while real-world evidence remains limited. This retrospective observational study aimed to evaluate and compare the effectiveness of these therapies during the first year...